The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Mycosis Fungoides: Disease Evolution and Prognosis of 309 Dutch Patients
Abstract
OBJECTIVES: To determine the disease course of Dutch patients with mycosis fungoides and to define factors related to disease progression and survival. DESIGN: A multicenter, 13-year, retrospective cohort analysis. SETTING: Eight dermatology departments collaborating in the Dutch Cutaneous Lymphoma Group. PATIENTS: Three hundred nine patients with mycosis fungoides registered between October 1985 and May 1997, including 89 patients with limited patches or plaques (stage Ia), 135 with generalized patches or plaques (stage Ib), 46 with skin tumors (stage Ic), 18 with enlarged but uninvolved lymph nodes (stage II), 18 with lymph node involvement (stage III), and 3 with visceral involvement (stage IV). MAIN OUTCOME MEASURES: Response to initial treatment, sustained complete remission, actuarial disease progression, and overall and disease-specific survival per clinical stage. RESULTS: The median follow-up was 62 months (range, 1-113 months). For the entire group, the actuarial overall and disease-specific survival was 80% and 89% at 5 years, and 57% and 75% at 10 years, respectively. The actuarial 5-year disease-specific survival of patients with stage Ia, Ib, and Ic disease was 100%, 96%, and 80%, respectively, and only 40% for patients with stage III disease. Using multivariate analysis, the presence of extracutaneous disease, the type and extent of skin involvement, the response to initial treatment, and the presence of follicular mucinosis were independently associated with higher disease progression and mortality rates. The calculated risks of disease progression at 5 and 10 years gradually increased from 4% to 10% for those with stage Ia disease, from 21% to 39% for those with stage Ib disease, and from 32% to 60% for those with stage Ic disease; for those with stage III disease, the risk remained at 70% at 5 and 10 years. The overall risk of disease progression at 5 and 10 years was 24% and 38%, respectively, for the total study group. CONCLUSION: At least within the first 10 years after diagnosis, disease progression and mycosis fungoides-related mortality occur in only a subset of patients generally presenting with advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Multiclass cancer diagnosis using tumor gene expression signatures
Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C.-H., Angelo, M., Ladd, C., Reich, M., Latulippe, E., Mesirov, J. P., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211566398 · Cited by 2,023
Willemze, R., Kerl, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, M. S., Díaz-Pérez, J. L., Geerts, M., Goos, M., Knobler, R., et al. (1997) · PubMed · doi:10.1182/blood.v90.1.354 · Cited by 1,270
Self-citationWong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H.-L., Steinman, R. M., & Choi, Y. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2075 · Cited by 853
Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations
Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K.-M., Johnson, M., Lynch, D., Tsien, R. Y., & Lenardo, M. J. (2000) · Science · doi:10.1126/science.288.5475.2354 · Cited by 662
Multiple roles of eph receptors and ephrins in neural development
Wilkinson, D. G. (2001) · Nature Reviews Neuroscience · doi:10.1038/35058515 · Cited by 610
T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance
Suzuki, A., Yamaguchi, M. T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00134-0 · Cited by 589
Cited by
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
Self-citationAgar, N. S., Wedgeworth, E., Crichton, S., Mitchell, T. J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C. M., Wain, E. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7665 · Cited by 853
Bekkenk, M. W., Geelen, F. A. M. J., Vader, P. C. V. V., Heule, F., Geerts, M.-L., van Vloten, W. A., Meijer, C. J. L. M., & Willemze, R. (2000) · Blood · doi:10.1182/blood.v95.12.3653 · Cited by 800
Self-citationKim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 653
Scarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., Stadler, R., Wood, G. S., Beylot-Barry, M., Pham-Ledard, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.7142 · Cited by 430
Self-citationEORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., D’Incan, M., Ranki, A., Pimpinelli, N., Ortiz-Romero, P., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.025 · Cited by 416
Self-citationvan Doorn, R., Scheffer, E., & Willemze, R. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.2.191 · Cited by 331
Self-citationLong-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009
Talpur, R., Singh, L., Daulat, S., Liu, P., Seyfer, S., Trynosky, T., Wei, W., & Duvic, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0604 · Cited by 289
Clinicopathological spectrum of mycosis fungoides
Kazakov, D., Burg, G., & Kempf, W. (2004) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2004.00937.x · Cited by 262
Scarisbrick, J. J., Quaglino, P., Prince, H. M., Papadavid, E., Hodak, E., Bagot, M., Servitje, O., Berti, E., Ortiz‐Romero, P., Stadler, R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17258 · Cited by 244
Self-citationReal-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Hodak, E., Geskin, L., Guenova, E., Ortiz-Romero, P. L., Willemze, R., Zheng, J., Cowan, R., Foss, F., Mangas, C., & Querfeld, C. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00732-w · Cited by 47
Self-citationDoeleman, T., Brussee, S., Hondelink, L. M., Westerbeek, D. W. F., Sequeira, A. M., Valkema, P. A., Jansen, P. M., He, J., Vermeer, M. H., Quint, K. D., et al. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.07.036 · Cited by 7
Metadata
- Authors
- van Doorn, R., Van Haselen, C. W., van Voorst Vader, P. C., Geerts, M.-L., Heule, F., de Rie, M., Steijlen, P. M., Dekker, S. K., van Vloten, W. A., & Willemze, R.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2000-04-01
- Volume
- 136
- Issue
- 4
- Pages
- 504-10
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2146015805
- Cited by
- 367
- References
- 53
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.